Skip to content

Prophylactic Negative Pressure Wound Therapy for High Risk Laparotomy Wounds. A Randomized Prospective Clinical Trial.

Prophylactic Negative Pressure Wound Therapy for High Risk Laparotomy Wounds. Randomized Prospective Clinical Trial.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03716687
Enrollment
100
Registered
2018-10-23
Start date
2018-11-01
Completion date
2020-09-01
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dehiscence of Internal Surgical Wound, Surgical Site Infection, Surgical Wound, Wound Dehiscence, Surgical

Keywords

negative pressure wound closure, surgical site infection, cost effectiveness

Brief summary

Negative pressure wound closure technique (NPWT) has been widely introduced in different clinical settings. Most of the studies report it as an effective and cost-effective method to treat complicated surgical wounds or even open abdomen. NPWT as a prophylactic effort to prevent complications of high risk surgical wounds has recently been introduced, but the concept is still lacking clinical evidence in terms of clinical effectiveness and cost effectiveness. In this randomized, multi centric study investigators aim to compare prophylactic negative pressure wound closure (ciNPWT) with traditional, dry wound dressing at high infection risk laparotomy wounds.

Detailed description

The aim is to compare ciNPWT (closed incisional negative pressure wound dress) technique to the traditional, dry wound dressing technique at high infection risk laparotomy wounds. Control arm will be treated as usual: sterile gauze or high-absorbing surgical wound dress. Experimental arm will be dressed with: one layer of silver-containing, impregnated mesh laxer (Atrauman® Ag - Hartmann) directly placed on the primary closed wound, one layer of alcohol-soaked foam (VivanoMed® White Foam - Hartmann) and sufficient-size sealant film (Hydrofilm® - Hartmann). A negative pressure of -90 Hgmm will be administered in a continuous mode over 5 days postoperatively. Surgical site infection and abdominal wall dehiscence rate will be assessed, as well as cost effectiveness will be calculated at both arms.

Interventions

DEVICEProphylactic negative pressure wound dressing after laparotomy

Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.

Sponsors

Semmelweis University
CollaboratorOTHER
Department of Surgery, Jahn Ferend Dél-Pesti Kórház és Rendelőintézet, Budapest
CollaboratorUNKNOWN
Department of Surgery, Somogy Megyei Kaposi Mór Oktatókórház, Kaposvár
CollaboratorUNKNOWN
Institute of Surgery, University of Debrecen
CollaboratorUNKNOWN
Department of Surgery, University of Szeged
CollaboratorUNKNOWN
Department of Surgery, Uzsoki Utcai Kórház és Rendelőintézet, Budapest
CollaboratorUNKNOWN
Department of Surgery, Markusovszky Egyetemi Oktatókórház, Szombathely
CollaboratorUNKNOWN
Department of Surgery, Bács-Kiskun Megyei Kórház, Kecskemét
CollaboratorUNKNOWN
Department of Surgery, Kenézy Gyula Egyetemi Oktatókórház, Debrecen
CollaboratorUNKNOWN
Department of Surgery, Szent Rókus Kórház, Baja
CollaboratorUNKNOWN
Department of Surgery, St. Borbala hospital, Tatabanya
CollaboratorUNKNOWN
St. Borbala Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

50-50% randomisation into interventional (ciNPWT) and control (traditionaltreatment) groups.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* High risk laparotomy patients. SSI risk at least 3x higher than normal rate (6-8%) * Surgical wound type III or IV..

Exclusion criteria

* Patients not giving informed consent. * Patients requiring open abdominal wound care. * Patients with abdominal wall malignancy, * Patients with peritoneal carcinomatosis, * Patients who are planned for second look laparotomy within 5 days, * Patients with less thank 3 month life expectancy. * Patients who are operated with existing wound infection

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infection30 daysSurgical site infection requiring wound re-opening (suture removal) and open wound treatment. (Clavien-Dindo 2)

Secondary

MeasureTime frameDescription
Full thickness abdominal wall dehiscence, requiring re-operation30 daysFull thickness abdominal wall dehiscence, requiring re-operation

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026